Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2022-01-27 Major Shareholding Noti…
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2022-01-27 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a clinical study result and references incorporation by reference into various registration statements. The document length is 2336 characters, which is relatively short and primarily serves as an announcement of information rather than a full report. Form 6-K filings are typically used for current reports by foreign private issuers and often contain press releases or other material information updates. This document does not contain detailed financial statements or comprehensive analysis, so it is not an Annual Report (10-K) or Interim Report (IR). It is also not a certification or officer attestation. Given the short length and nature of the content, this fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-01-13 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is a registration statement under the Securities Act of 1933 for securities to be issued under an employee benefit plan (Amended and Restated Award Plan). It includes detailed information about the securities to be registered, incorporation by reference of other filings, indemnification of directors and officers, and insurance policies. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and employee stock plans. Therefore, it fits best under Regulatory Filings (RNS) as it does not match any other specific report category and is a general SEC filing for registration purposes.
2022-01-11 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a license agreement for a pharmaceutical product. The document length is 2303 characters, which is relatively short and mainly serves as an announcement rather than a detailed report. It does not contain financial statements or detailed financial analysis. The document is not an annual or interim report, nor is it a transcript, audit report, or management report. It is a regulatory filing used to disclose material information by foreign issuers. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-01-06 English
6-K
Director's Dealing Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release titled 'RedHill Biopharma Announces Additional Insider Buying.' The document length is 2246 characters, which is relatively short and primarily serves as an announcement rather than a detailed report. The content focuses on insider buying activity, which relates to transactions by company insiders. Given the nature of the announcement about insider buying and the form type (6-K), this fits best under the category of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades).
2021-12-15 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about a publication related to antibiotic resistance rates. The document is short (2376 characters) and primarily serves as a regulatory filing to disclose information to the SEC and investors. It does not contain financial statements, detailed financial analysis, or management discussion. It is not an annual or quarterly report, nor is it a call transcript or other specific report type. The document is a regulatory announcement of a press release, fitting the category of Regulatory Filings (RNS) as a general disclosure that does not fit other categories.
2021-12-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.